1. HBW Insight
  2. >>Ingredients & Safety

Sunscreen Industry's Plan For First Ingredient MUsT Estimates 2023 Completion

 
• By Eileen Francis

Personal Care Product Council submits work plan to FDA setting 2023 date for completing MUsT trial on one of eight UV filters, with additional trials to follow. Research firm considers the estimate consistent with the industry's experience with the trials, but says it could design and conduct the required pilot and pivotal studies in six months.

UV Protection. UV reflection skin before and after protection. Protect and Support healthy skin in the sun - Vector

The sunscreen product industry’s work plan for tests to support the safety and effectiveness of eight UV filters that could be removed from the US market under a proposed rule sets a 2023 completion date for a maximum usage trial on the first formulation.

Meanwhile, an executive with a research firm that has conducted MUsT sunscreen ingredient trials for the Food and Drug Administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By David Ridley

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 
• By Malcolm Spicer

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

More from HBW Insight

Valbiotis Launches Plant-Based Heart Health Supplement

 
• By Tom Gallen

Available in French pharmacies and online, ValbiotisPRO Cardio-circulation comprises a blend of six plant extracts and is targeted at those with high blood pressure.

L’Oréal, NVIDIA Partner To ‘Unlock’ AI’s Potential Across Beauty

 
• By Eileen Francis

L’Oréal SA and NVIDIA Corp. are collaborating to unlock AI’s potential access across beauty, including innovation, scalability, and personalized marketing, the French beauty firm and the tech company announced during the Viva Technology show in Paris.

Xlear Lawsuit Argues To Shelve FTC Policy For Health Claim Substantiation Under Loper Bright

 
• By Malcolm Spicer

Complaint filed Utah federal court says “Supreme Court explicitly rejected Chevron deference to agency interpretations” in the Loper decision, compelling rejection of “an agency’s statutory interpretation unless the court, ‘after applying all relevant interpretive tools, concludes’ the interpretatio